文献速递脊柱关节炎

银屑病关节炎患者在接受肿瘤坏死因子抑制剂治疗时接种BNT162b2 mRNA SARS-CoV-2疫苗的免疫原性

Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors.
PubMed 文献 · RMD Open · 2022-01-01

纳入40例接受肿瘤坏死因子抑制剂(TNFi)治疗的银屑病关节炎(PsA)患者,接种BNT162b2 mRNA SARS-CoV-2疫苗第二剂后15天检测抗SARS-CoV-2 IgG,并与健康对照进行1:1倾向评分匹配比较。结论认为疫苗接种期间继续TNFi未损害免疫原性。

要点

  • PsA患者接种BNT162b2后抗SARS-CoV-2 IgG阳性,平均13794.44±15815.42 AU/mL。
  • 疫苗接种期间继续TNFi未损害免疫原性。

核心结论

  • 在PsA患者中,整个疫苗接种期间继续TNFi未损害免疫原性。

研究设计与样本

  • 纳入40例分类明确的PsA患者,均接受TNFi并接种BNT162b2 mRNA SARS-CoV-2疫苗(BioNTech/Pfizer)。
  • 第二剂后15天检测血清抗SARS-CoV-2 IgG(Abbott ARCHITECT i2000SR,阳性截断值50 AU/mL),并收集临床指标与治疗数据。
  • 以医护人员血清作为健康对照进行1:1倾向评分匹配,对照均未用药。
  • 采用Student t检验和逻辑回归分析组间免疫原性差异及抗体应答预测因素。

主要发现

  • 疫苗接种前后临床疾病活动指数无变化(7.06±5.23至7.10±5.27,p=0.92)。
  • PsA患者抗SARS-CoV-2 IgG阳性,平均±SD为13794.44±15815.42 AU/mL。
  • 总体样本中,使用甲氨蝶呤者(12/80,15%)免疫应答有降低趋势(p=0.07);糖皮质激素治疗(11/80,13.8%)预测较低抗体水平(p=0.04)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scanty data on the immunogenicity of the BNT162b2 vaccine in patients with psoriatic arthritis (PsA) on Tumor Necrosis Factor inhibitors (TNFi) have been published. OBJECTIVE: To investigate the humoral response to BNT162b2 vaccination patients with PsA on TNFi, comparing immunogenicity with healthy controls. METHODS: Forty patients with classified PsA on TNFi undergoing vaccination with the BNT162b2 mRNA SARS-CoV-2 vaccine (BioNTech/Pfizer) were enrolled. Fifteen days after the second shot, serum IgG levels against SARS-CoV-2 (Abbott ARCHITECT i2000SR, positivity cut-off 50 AU/mL) were assayed in all patients. Clinimetrics and treatment data were gathered. TNFi treatment was not discontinued throughout the whole period, whereas methotrexate (MTX) was discontinued for 1 week after each shot in those on combination therapy. Sera from healthcare professionals were considered as healthy controls for 1:1 propensity score matching; any of them was taking medication.Student's t-test and logistic regression were used for investigating differences in immunogenicity between groups and predictors of antibody response. RESULTS: Clinical Disease Activity Index did not change before and after vaccination (7.06±5.23 to 7.10±5.27, p=0.92).Patients with PsA achieved a positive anti-SARS-CoV-2 IgG level with a mean (±SD) of 13794.44±15 815.42 AU/mL. Although lower, the antibody level was not significantly different from matched controls (19227.4±11.8460.45 AU/mL, p=0.08). In the overall sample, those on MTX (12/80, 15%) had a trend toward lower immune response (p=0.07); glucocorticoid therapy (11/80, 13.8%) predicted lower antibody levels (p=0.04). CONCLUSIONS: Continuing TNFi in patients with PsA throughout the vaccination did not hamper immunogenicity.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Venerito V, Stefanizzi P, Fornaro M, et al. Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors. RMD Open. 2022. PMID: 34987092. doi:10.1136/rmdopen-2021-001847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。